Cancer Therapy News and Research

RSS

First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix

A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.

16 Mar 2011

Prophylactic PEG placement prior to HNC therapy associated with high rate of non use

Impairment of oral intake occurs in the majority of patients with head and neck cancer (HNC) receiving chemoradiotherapy. Placement of prophylactic percutaneous endoscopic gastrostomy (PEG) tube in asymptomatic newly diagnosed HNC before chemoradiation is a common practice in some centers. In some studies, PEG has been associated with a decrease in treatment related weight loss in patients with HNC, but no studies have examined the utilization rate.

16 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

AYA cancer patients require targeted care, say experts

Adolescents and young adults are neither children nor adults and those affected by cancer require targeted care that crosses the boundaries between pediatric and adult oncology, according to several pioneers in this still-developing field of adolescent and young adult oncology.

15 Mar 2011

TESE surgical technique can help men with childhood cancer experience parenthood

A new study has shown that a surgical technique called microdissection testicular sperm extraction can effectively locate and extract viable sperm in more than one-third of adult male childhood cancer survivors who were previously considered sterile due to prior chemotherapy treatment.

15 Mar 2011

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.

14 Mar 2011

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows.

14 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

Canadian Partnership to receive second mandate from Harper Government for cancer control

Today's announcement of renewed support for cancer control by Prime Minister Harper is great news for Canadians. The Canadian Partnership Against Cancer is receiving a second five-year mandate, to begin in 2012, and $250 million in funding to continue implementation of Canada's national cancer control strategy.

11 Mar 2011

Increase in cancer survivors underscores need for post-treatment follow-up care

The number of cancer survivors in the United States increased to 11.7 million in 2007, according to a report the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) released today. This is a nearly 20 percent increase in cancer survivors from 2001.

11 Mar 2011

Simcere files IND with SFDA of China for APX003 to treat cancer

Apexigen, Inc., an emerging biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, announced today that its partner, Simcere Pharmaceutical Group, a leading pharmaceutical company in China, filed an Investigational New Drug application with the State Food and Drug Administration of China to evaluate APX003 as a potential cancer therapy.

11 Mar 2011

SAP may serve as effective nanomaterial to prevent prostate cancer spread

When prostate cancer stem cells were enclosed in self-assembling nanomaterials made of peptides, the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

Despite dramatically improved survival rates for childhood acute lymphoblastic leukemia, relapse remains a leading cause of death from the disease. Work led by St. Jude Children's Research Hospital investigators identified mutations in a gene named CREBBP that may help the cancer resist steroid treatment and fuel ALL's return.

10 Mar 2011

CRT, ICR sign deal with ZoBio to discover and develop cancer drugs

Cancer Research Technology and The Institute of Cancer Research have signed a deal with Dutch drug discovery company, ZoBio BV, to discover and develop drugs to block a DNA repair target which may play a role in cancer cell survival.

10 Mar 2011

ADVANTAGE, ITA to implement proprietary oncology decision-support platform

To improve outcomes and manage costs for members with cancer, ADVANTAGE Health Solutions, Inc. has contracted with ITA Partners to implement eviti - ITA's proprietary oncology decision-support platform - across their provider network.

9 Mar 2011

NHMRC awards $38.4M for cancer and blood cell research

Institute research into how cancer develops and blood cell production and function will today be awarded $38.4 million under the National Health and Medical Research Council's (NHMRC) program grants scheme.

9 Mar 2011

Chemotherapy drugs also kill malaria parasite

A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.

9 Mar 2011

ADAM-12 gene can serve as treatment target for cancer, arthritis, cardiac hypertrophy

ADAM-12 is not only the name of a 1970's television police drama - it's also the gene that University of Missouri researchers believe could be an important element in the fight against cancer, arthritis, and cardiac hypertrophy, or thickening of the heart's walls.

9 Mar 2011

New insight into malaria

A group of researchers from EPFL's Global Health Institute and Inserm has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria.

8 Mar 2011

Cancer Therapy News and Research

First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix

Prophylactic PEG placement prior to HNC therapy associated with high rate of non use

Apeiron in antitumor substances deal with Cleveland Clinic

AYA cancer patients require targeted care, say experts

TESE surgical technique can help men with childhood cancer experience parenthood

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

Canadian Partnership to receive second mandate from Harper Government for cancer control

Increase in cancer survivors underscores need for post-treatment follow-up care

Simcere files IND with SFDA of China for APX003 to treat cancer

SAP may serve as effective nanomaterial to prevent prostate cancer spread

Idera reports $6.0 million net loss for fourth quarter 2010

Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

CRT, ICR sign deal with ZoBio to discover and develop cancer drugs

ADVANTAGE, ITA to implement proprietary oncology decision-support platform

NHMRC awards $38.4M for cancer and blood cell research

Chemotherapy drugs also kill malaria parasite

ADAM-12 gene can serve as treatment target for cancer, arthritis, cardiac hypertrophy

New insight into malaria

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News